文献速递肝病消化道肿瘤与早癌消化内镜

肝细胞癌局部治疗结局评分系统:系统综述

Outcome scoring systems for locoregional therapy in hepatocellular carcinoma: a systematic review.
PubMed 文献 · Gut · 2026-07-09

大多数模型存在高偏倚风险,仅12.3%研究为低偏倚风险;部分评分系统在特定治疗和人群中表现出较好区分度。

要点

  • 179个评分系统预测局部治疗结局,AUROC范围0.56–0.94。
  • 仅16项研究(12.3%)为低偏倚风险,多数模型存在高偏倚风险。
  • HAP和mHAP-II汇总区分度最高(汇总AUROC>0.72)。

核心结论

  • 多个结局评分系统在特定局部治疗和人群中具有应用前景,但多数模型存在高偏倚风险,需进一步开发和验证。

主要发现

  • 纳入患者中女性占21%(范围4–51%),多数为巴塞罗那临床肝癌B期(39%)。
  • 评分系统常纳入肿瘤参数、肝功能检查、肝硬化分期和合并症。
  • AUROC值范围为0.56至0.94。
  • 16项研究(12.3%)为低偏倚风险,多数为高偏倚风险。
  • Y-scoring系统、Cheng等列线图和Li等列线图在姑息性局部治疗中预测总生存的区分度最高(AUROC>0.87)。

关键数值与推荐

  • HAP和mHAP-II评分汇总区分度最高(汇总AUROC>0.72)。
  • Six-and-Twelve评分汇总AUROC为0.68,ALBI评分为0.60,表现较低。

临床怎么用

  • 临床可参考HAP、mHAP-II等评分辅助评估局部治疗预后,但需注意多数模型偏倚风险高,应用前应结合具体治疗和人群验证。

局限性

  • 多数纳入模型存在高偏倚风险,仅12.3%研究为低偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Locoregional therapy (LRT) is frequently used as bridging therapy to transplantation/resection or palliative treatment for hepatocellular carcinoma (HCC). Multiple prediction models have been developed for prognosis and treatment response among patients undergoing LRTs. OBJECTIVE: We aimed to systematically review the methodological quality and performance of clinical risk scores predicting outcomes in patients with HCC treated with LRT. DESIGN: EMBASE and PubMed were searched from inception to 18 March 2026. Our main outcome was the concordance statistic, or area under the receiver operating characteristic curve (AUROC), to predict survival and other tumour-related and liver-related outcomes. RESULTS: 130 studies met the inclusion criteria, resulting in 179 individual scoring systems. The total population was 70 061 patients, 21% female (4-51%), most with Barcelona Clinic Liver Cancer Stage B (39%). Risk scores commonly incorporated tumour parameters, liver function tests, cirrhosis staging and comorbidities. AUROC values ranged from 0.56 to 0.94. 16 studies (12.3%) had low risk of bias, while most had high risk of bias. Of these, the Y-scoring system, Cheng et al nomogram and Li et al nomogram showed the highest discrimination for overall survival in palliative LRT (AUROC >0.87). Separate pooled analyses showed that the Hepatoma Arterial-embolisation Prognostic (HAP) and modified Hepatoma Arterial-embolisation Prognostic II (mHAP-II) scores had the highest performance (pooled AUROC >0.72), while the Six-and-Twelve (0.68) and Albumin-Bilirubin (ALBI) scores (0.60) demonstrated lower performance. CONCLUSION: Several outcome scoring systems are promising for specific LRTs and populations. However, most models have high risk of bias, underscoring the need for further development and validation.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Daruwalla C, Calderon E, Mathew C, et al. Outcome scoring systems for locoregional therapy in hepatocellular carcinoma: a systematic review. Gut. 2026. PMID: 42425732. doi:10.1136/gutjnl-2025-337557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。